PsychoGenics Receives $3M SBIR Grant from NIMH to Advance AI-Enabled Drug Discovery
PsychoGenics offers a comprehensive suite of capabilities, including standard behavioral testing, electrophysiology, translational EEG, molecular biology, microdialysis, and quantitative immunohistochemistry.
Company Name: PsychoGenics
Location: Paramus, NJ
Sector: Biotechnology, AI-Enabled Phenotypic Drug Discovery
Funding Details: Received $3 million in SBIR Grant funding from the National Institute of Mental Health (NIMH).
Purpose of Investment: The company plans to use the funds to further develop eCube®, its proprietary AI-enabled EEG platform, along with its machine learning tools, to identify novel applications for existing drugs targeting rare diseases.
Product and Innovation: Led by CEO Emer Leahy and CIO/CTO Daniela Brunner, PsychoGenics is a biotechnology company focused on advancing drug discovery through its AI-enabled phenotypic platforms. The company has developed several proprietary platforms, including SmartCube®, NeuroCube®, PhenoCube®, and eCube®, which are used to translate rodent behavioral and physiological responses into high-throughput and high-content phenotyping. These platforms have been successfully used in shared-risk partnerships with pharmaceutical companies, leading to the discovery of novel compounds now in advanced preclinical development and clinical trials.
About the Company: PsychoGenics offers a comprehensive suite of capabilities, including standard behavioral testing, electrophysiology, translational EEG, molecular biology, microdialysis, and quantitative immunohistochemistry. The company also provides various mouse models to support research in areas such as Huntington’s disease, autism spectrum disorders, pain, psychosis/schizophrenia, depression, PTSD, Alzheimer’s disease, Parkinson’s disease, neuromuscular disorders, and seizure disorders.
